65,437 trials
Hip Fracture
Primary: Total Hip Bone Mineral Density (BMD) at Baseline, 6 and 12 Months After Hip Fracture. — -0.008; 0.005; -0.017; -0.012 g/cm^2 — p=0.05
Cystic Fibrosis
Primary: Change From Baseline in Sputum Bacterial Load — -2.1; -1.03; -1.28; -1.7 log 10 cfu/ml
Actinic Keratosis
Primary: Percentage of Participants With Complete Response of Actinic Keratosis — 43; 32 percentage of participants
Healthy Volunteer
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast — 2832; 3235 h*ng/mL
Obesity · Patient Education · Weight Loss
Primary: Recruitment — 42 Participants
Asthma
Primary: Change From Baseline in Basophils, Full Analysis Set — 0.014; 0.012; 0.013 10^9 cells/L
Liver Cancer
Primary: Overall Image Quality of Magnetic Resonance Elastography (MRE)
Avascular Necrosis · Post-traumatic; Arthrosis · Knee Osteoarthritis
Primary: Component Alignment — 179; 178 degree — p=0.2342
Respiratory Syncytial Viruses
Primary: Area Under the Viral Load-time Curve (VL-AUC) — 19.94; 14.74; 16.44; 15.33 log10 copies-/ml*days — p=0.808
Diabetes Mellitus
Primary: Accuracy of Glucose Concentrations (%) — 97.4 percentage of measurements within range
Rabies
Primary: Geometric Mean Titer (GMT) 14 Days Post Fourth Dose Post Exposure Prophylaxis (PEP) With Purified Chick Embryo Cell Vaccine (PCECV) in Each Malaria Prophylaxis Group…
Ametropia
Primary: Symptom of Burning — 0.16; 0.21; 1.00; 1.00 units on a scale
Esophageal Cancer
Primary: Pathologic Complete Response (PCR) Rate
Kidney Cancer
Primary: Proportion of Patients With Response — 0.18; 0.11 proportion of participants
Hepatic Impairment · Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) — 532.2; 835.5; 668.3; 658.6 nanogram per milliliter (ng/mL)